Skip to content

Study · Case report or series · n = 1 · 2026

6 results

Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.

Mohammed A, Mishra S

AACE endocrinology and diabetes29 Sept 2025

PMID41641313 (opens in a new tab)PMCIDPMC12866074 (opens in a new tab)DOI10.1016/j.aed.2025.09.012 (opens in a new tab)PepBankPUB-41641313
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 65-year-old woman with obesity, weekly subcutaneous tirzepatide for 4 months was followed by a moderate reduction in body mass index.

    In plain wordsOne 65-year-old woman with obesity had a moderate fall in body mass index on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody mass index
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    She had a moderate reduction in body mass index over 4 months, with a modest reduction in fat mass and a substantial reduction in lean mass.
    1 context sentence
    Summary · context
    We measured the body compositions of 2 older women with obesity, who were unable to lose weight through lifestyle changes alone, before and after taking GLP-1 RAs.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 65-year-old woman with obesity, weekly subcutaneous tirzepatide for 4 months was followed by a modest reduction in fat mass.

    In plain wordsOne 65-year-old woman with obesity had a small fall in fat mass on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFat mass
    Study

    n = 1

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    She had a moderate reduction in body mass index over 4 months, with a modest reduction in fat mass and a substantial reduction in lean mass.
    1 context sentence
    Summary · context
    We measured the body compositions of 2 older women with obesity, who were unable to lose weight through lifestyle changes alone, before and after taking GLP-1 RAs.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 65-year-old woman with obesity, weekly subcutaneous tirzepatide for 4 months was followed by a substantial reduction in lean mass.

    In plain wordsOne 65-year-old woman with obesity had a large fall in lean mass on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLean mass
    Study

    n = 1

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    She had a moderate reduction in body mass index over 4 months, with a modest reduction in fat mass and a substantial reduction in lean mass.
    1 context sentence
    Summary · context
    We measured the body compositions of 2 older women with obesity, who were unable to lose weight through lifestyle changes alone, before and after taking GLP-1 RAs.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 79-year-old woman with obesity, weekly subcutaneous semaglutide for 6 months was followed by a moderate reduction in body mass index.

    In plain wordsOne 79-year-old woman with obesity had a moderate fall in body mass index on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The second patient (79 years old) received weekly subcutaneous injections of semaglutide and had a moderate reduction in body mass index over 6 months, with a substantial reduction in fat mass and a modest gain in lean mass.
    1 context sentence
    Summary · context
    We measured the body compositions of 2 older women with obesity, who were unable to lose weight through lifestyle changes alone, before and after taking GLP-1 RAs.
  5. 05HumanCase report or seriesEfficacy outcome

    In a 79-year-old woman with obesity, weekly subcutaneous semaglutide for 6 months was followed by a substantial reduction in fat mass.

    In plain wordsOne 79-year-old woman with obesity had a large fall in fat mass on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass
    Study

    n = 1

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The second patient (79 years old) received weekly subcutaneous injections of semaglutide and had a moderate reduction in body mass index over 6 months, with a substantial reduction in fat mass and a modest gain in lean mass.
    1 context sentence
    Summary · context
    We measured the body compositions of 2 older women with obesity, who were unable to lose weight through lifestyle changes alone, before and after taking GLP-1 RAs.
  6. 06HumanCase report or seriesEfficacy outcome

    In a 79-year-old woman with obesity, weekly subcutaneous semaglutide for 6 months was followed by a modest gain in lean mass.

    In plain wordsOne 79-year-old woman with obesity had a small gain in lean mass on semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseLean mass
    Study

    n = 1

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The second patient (79 years old) received weekly subcutaneous injections of semaglutide and had a moderate reduction in body mass index over 6 months, with a substantial reduction in fat mass and a modest gain in lean mass.
    1 context sentence
    Summary · context
    We measured the body compositions of 2 older women with obesity, who were unable to lose weight through lifestyle changes alone, before and after taking GLP-1 RAs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.